Full-Time

Associate Director Data Master

Global Capability Owner

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

Compensation Overview

$160k - $240k/yr

+ Discretionary annual cash bonus + Equity grants

Pennsylvania, USA

Hybrid

US-based candidates only. Travel 20-30% required.

Bachelor's, MBA

Category
Data & Analytics
Required Skills
Product Management
Data Governance
Data Analysis

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Requirements
  • Bachelor’s degree in business, technology, marketing, science, or related field.
  • 8+ years of experience in data mastering in pharmaceutical or healthcare industries
  • Experience in digital product management, product ownership, or demonstrated experience managing the creation and delivery of a product roadmap within a cross-functional team.
  • Experience working with global data platforms, data governance solutions, MDM tools, CRM systems, reporting tools, or comparable technologies.
  • Strong understanding of commercial data and how they support business needs in pharmaceutical or healthcare industries.
Responsibilities
  • Define and articulate the capability vision, and outcomes aligned to global and franchise priorities in collaboration with key stakeholders.
  • Own and continuously evolve the US Data Master roadmap, making prioritization and trade-off decisions to add the most value based upon user feedback and aligned with customer experience data strategy.
  • Translate global and regional business strategies into clear team-level plans, ensuring work is sequenced, prioritized, and resourced to deliver against the most critical needs.
  • Partner with business leadership to translate business needs into capability solutions with measurable success metrics that drive impact across franchises and the business.
  • Develop and maintain a prioritized roadmap for data master domains, sequencing enhancements to improve data quality, coverage, latency, integration, and scalability in alignment with commercial needs and enterprise standards.
  • Connect business stakeholders and the Data Master capability team, ensuring requirements are clearly defined and aligned to strategically important business outcomes and success metrics.
  • Partner with business leadership to ensure the Data Master global capability team delivers solutions that are strategically aligned with key business outcomes and defined success metrics.
  • Partner closely with Global Capability Owners and Tech Lead to align capability priorities with data architecture, platform capabilities, and technical feasibility, ensuring trade-offs support global data strategy and delivery sequencing.
  • Partner across the Customer Experience Organization to support seamless integration and ongoing capability evolution to support scalability, flexibility, and compliance requirements.
  • Deliver standardized, trusted master data and consent frameworks that enable downstream teams to operate on consistent customer and capability information across targeting, account planning, access, analytics, and reporting use cases.
  • Champion a user- and value-centric capability mindset, leveraging user insights, data usage patterns, and engagement metrics to inform the design and evolution of US Data Master capabilities that enhance usability and adoption for internal and external users.
  • Leverage user insights and engagement data to shape Data Master capabilities that drive an improved customer experience (for both internal and external users).
  • Lead discovery efforts, engaging directly with users and key stakeholders to deeply understand their needs, validate business value, and assess technical feasibility prior to development.
  • Partner across Global Capability teams to support the delivery of scalable, reusable Data Master capabilities.
  • Monitor capability adoption, outcome KPIs and engagement metrics to inform backlog prioritization and continuous improvement.
  • Responsible for completion of documentation (PRDs, user stories, discovery artifacts) using standard templates, and sprint planning in partnership with the Tech Lead and development teams.
  • Partner with data and platform teams to provide feedback on enterprise platforms and architecture, driving continuous improvement in outcomes and data quality, usability, and performance while leveraging standardized enterprise solutions.
  • Leverage outcome metrics to support the articulation of the capability's value proposition and its impact, promoting capability awareness across CX operations and fostering a culture of engagement and feedback in partnership with Activation.
Desired Qualifications
  • Advanced degree (MBA or relevant graduate degree) preferred.
  • Experience working in the product operating model
  • Experience partnering with enterprise platform teams or product teams supporting digital and operational capabilities.
  • Experience working in rare disease or specialty brands, with strong understanding of unique stakeholder dynamics.

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue reached $1.21 billion, and full-year guidance rose to $4.60-$4.75 billion.
  • Ziihera approval on August 25, 2026 opens a $3 billion-$5 billion peak-sales opportunity.
  • Zepzelca and Xywav posted strong 2026 growth, validating Jazz's oncology and sleep franchises.

What critics are saying

  • Lupin, Teva, and Tris challenge Xywav and Xyrem, threatening 2027-2033 economics.
  • Granules settled in March 2026 with launch rights under confidential terms, pressuring Xywav pricing.
  • Jazz took on Actio for $820 million upfront; ABS-1230 still faces clinical and regulatory failure.

What makes Jazz Pharmaceuticals unique

  • Xywav owns narcolepsy and idiopathic hypersomnia through FDA orphan exclusivity until July 2027.
  • Epidiolex gives Jazz rare epilepsy scale, with durable U.S. brand recognition since 2021 GW acquisition.
  • Ziihera launch on August 25, 2026 expands Jazz into HER2-positive gastroesophageal cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
StockTitan
Aug 27th, 2026
Jazz Pharmaceuticals prices upsized $1.1B exchangeable notes offering with $225M share repurchase

Jazz Pharmaceuticals has priced an upsized $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, up from the previously announced $1.0 billion. The offering, conducted through its wholly-owned subsidiary Jazz Investments I Limited, is expected to close on 31 August 2026. The notes will mature on 15 September 2032 and are exchangeable at an initial rate of 2.8150 ordinary shares per $1,000 principal amount, equivalent to an exchange price of approximately $355.24 per share. This represents a 42.5% premium above the last reported sale price on 26 August 2026. The company will use net proceeds of approximately $1,079 million for general corporate purposes. Concurrently, Jazz Pharmaceuticals agreed to repurchase approximately $225 million of its ordinary shares from note purchasers at $249.29 per share, using existing cash on hand.

Yahoo Finance
Aug 26th, 2026
Jazz Pharmaceuticals launches Ziihera for HER2-positive cancer with $3B–$5B peak sales outlook

Jazz Pharmaceuticals has launched Ziihera in the US following FDA approval for first-line treatment of HER2-positive, unresectable or metastatic gastroesophageal adenocarcinoma. The drug can be used with tislelizumab and chemotherapy, or with chemotherapy alone for certain patients. In the Phase III HERIZON-GEA-01 trial, Ziihera-based regimens reduced the risk of disease progression or death by 35%. The triplet regimen extended median overall survival to 26.4 months, a 28% reduction in death risk versus trastuzumab. Jazz estimates the US addressable market at 3,000–4,000 patients annually and raised Ziihera's peak sales outlook to $3 billion–$5 billion. The company plans to leverage existing commercial infrastructure whilst pursuing additional cancer indications and international regulatory filings.

Yahoo Finance
Aug 11th, 2026
Jazz Pharmaceuticals Q2 revenue beats estimates at $1.21B, ups guidance to $4.68B

Jazz Pharmaceuticals reported a strong second quarter with revenue of $1.21 billion, beating analyst estimates of $1.12 billion and representing 15.5% year-on-year growth. The company raised its full-year revenue guidance to $4.68 billion from $4.38 billion. CEO Renée Galá attributed the performance to strong demand for flagship products like Xywav and Epidiolex, alongside accelerating uptake of new oncology therapies. Operating margin improved to 20.5%, up from negative 65.6% in the prior year quarter. However, adjusted earnings per share of $5.71 missed analyst expectations of $6.18. During the earnings call, analysts focused on Epidiolex's growth drivers, Xywav's sustainability amid potential generic competition, and zanidatamab's upcoming approval prospects.

Yahoo Finance
Aug 11th, 2026
Jazz Pharma raises 2026 guidance on record Q2 revenue of $1.2B, up 16%

Jazz Pharmaceuticals reported record second quarter revenue of $1.2 billion, representing 16% year-over-year growth. The company raised its full-year revenue guidance based on strong first-half performance. Chief executive officer Renée Galá attributed the results to execution across the company's diversified portfolio and sustained demand for its commercial products. The company is preparing to launch zanidatamab, with a PDUFA date of 25 August for treatment of first-line HER2-positive metastatic gastroesophageal adenocarcinoma. The earnings call included updates from senior leadership, including chief commercial officer Samantha Pearce, global head of research and development Robert Iannone, and chief financial officer Philip Johnson. Jazz Pharmaceuticals highlighted progress on its long-term value creation priorities whilst maintaining focus on current commercial operations.

Yahoo Finance
Aug 10th, 2026
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M upfront, adding KCNT1+ epilepsy therapy

Jazz Pharmaceuticals has agreed to acquire Actio Biosciences for $820 million upfront and up to $500 million in contingent payments. The deal adds ABS-1230, a clinical-stage precision therapy for KCNT1+ epilepsy, to Jazz's rare epilepsy portfolio. KCNT1+ epilepsy is a rare genetic condition affecting approximately 2,500 patients in the United States. Patients typically experience dozens to hundreds of seizures daily that resist standard medications. Around 80% of cases begin in infancy, with many children unable to reach basic developmental milestones. There are currently no FDA-approved therapies for KCNT1+ epilepsy. ABS-1230 recently showed meaningful seizure reductions in an early clinical trial. The ongoing Phase 1b/2a KYRON trial is designed as the registrational study supporting US new drug application submission.